证券日报网讯 10月13日晚间，生物股份发布公告称，公司控股子公司金宇益康生物技术（辽宁）股份 有限公司因经营发展需要，对其公司名称、法定代表人等信息进行了变更，相关工商变更登记手续已经 办理完毕，并取得换发后的《营业执照》。 （文章来源：证券日报） ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600201 | 生物股份 | 10.57 | 4.04% | 70.36万 | 7.25亿 | | 002688 | 金河生物 | 7.11 | 3.95% | 55.43万 | 3.93亿 | | 002141 | 后丰控股 | 3.96 | 2.86% | 45.10万 | 1.76亿 | | 300119 | 瑞普生物 | 22.15 | 1.28% | 11.53万 | 2.54亿 | | 688098 | 申联生物 | 10.46 | 0.97% | 5.93万 | 6137.71万 | | 603566 | 曾菜柯 | 14.16 | 0.43% | 4.88万 | 6872.97万 | | 300871 | 回盛生物 | 21.30 | -0.14% | 5.48万 | 1.16亿 | | 603718 | 海利生物 | 6.88 | -0.29% | 4.90万 | 3342.64万 | | 920970 | 大禹生物 | 9.3 ...

证券代码：600201 证券简称：生物股份 公告编号：临2025-056 金宇生物技术股份有限公司关于 控股子公司变更名称等信息暨完成工商变更的公告 本次控股子公司名称等信息变更是基于经营发展需要，不会导致公司主营业务 发生重大变化，不会对公司未来经营发展产生不利影响。 特此公告。 2.统一社会信用代码：91211000774602945W 3.法定代表人：高日明 4.注册资本：11,500 万元 5.成立日期：2005 年 4 月 30 日 6.住所：辽阳市太子河区南驻路 12 号 7.经营范围：生产、销售：细胞毒活疫苗、胚毒活疫苗、胚毒灭活疫苗、禽流 感灭活疫苗、卵黄抗体、细胞毒灭活疫苗、细菌灭活疫苗、细菌活疫苗；道路货物 运输；非国家强制免疫兽用生物制品销售。(依法须经批准的项目,经相关部门批准 后方可开展经营活动)。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，金宇生物技术股份有限公司（以下简称"公司"）控股子公司金宇益康 生物技术(辽宁)股份有限公司因经营发展需要，对其公司名称、法定代表人等信息 进行了变更 ...

Core Viewpoint - The agricultural, animal husbandry, and fishery sector showed strong performance on October 10, with the first agricultural ETF (159275) experiencing a significant increase in net subscriptions and notable gains in constituent stocks [1][3]. Market Performance - The agricultural ETF (159275) opened lower but quickly rebounded, closing up 0.8% after reaching a maximum intraday gain of 1.5%. It recorded a net subscription of 52 million units by the end of the day [1]. - Key stocks in the sector, such as TianKang Biological and GuanNong Co., saw increases exceeding 7%, while several others, including XiongDi Technology and ShengWu Shares, rose over 4% [1]. Industry Dynamics - The pig farming industry is undergoing capacity reduction, with a reported decrease of 400,000 breeding sows compared to the previous month and a total reduction of 3.4 million from the peak last year [2]. - Recent outbreaks of African swine fever in Vietnam and Guangxi, China, have heightened risks for the farming sector. A meeting on September 16 emphasized policies aimed at reducing production capacity [2][3]. Investment Outlook - Analysts from Pacific Securities and Dongfang Securities suggest that the current fundamentals and policy changes favor capacity reduction in the pig farming industry, indicating potential long-term investment value as most listed companies are at historical low valuations [3][4]. - The agricultural sector's valuation remains low, with the agricultural ETF's underlying index trading at a price-to-book ratio of 2.61, which is in the lower 34.9% of the past decade, suggesting a favorable entry point for investors [3]. Future Trends - The trend towards improving quality and efficiency in the pig farming industry is expected to continue, with outdated capacities being phased out and market dynamics shifting towards higher prices in the long term [4][5]. - Investment opportunities are identified in various segments, including pig farming, feed, animal health, and crop planting, as the demand for these sectors is anticipated to rise with the recovery of pig stocks [5][6].

Core Insights - The animal vaccine sector has seen a rise of 1.93%, ranking fourth among concept sectors in terms of growth, with 17 stocks increasing in value, led by TianKang Biological, BioShares, and Hengtong Holdings, which rose by 7.52%, 4.42%, and 4.24% respectively [1][2] - The sector experienced a net inflow of 178 million yuan from main funds, with 14 stocks receiving net inflows, and 6 stocks exceeding 10 million yuan in net inflows, with BioShares leading at 64.02 million yuan [2][3] - The top three stocks by net inflow ratio were HaiZheng Pharmaceutical, KeQian Biological, and TianKang Biological, with net inflow ratios of 13.58%, 10.61%, and 8.79% respectively [3][4] Sector Performance - The animal vaccine sector's performance is highlighted by the significant gains of key stocks, with TianKang Biological showing the highest increase at 7.52% and BioShares following closely at 4.42% [1][2] - The overall market sentiment for the animal vaccine sector appears positive, as indicated by the net inflow of funds and the number of stocks experiencing gains [2][3] Fund Flow Analysis - The main funds have shown a strong interest in the animal vaccine sector, with a total net inflow of 178 million yuan, indicating robust investor confidence [2][3] - The stocks with the highest net inflow include BioShares, TianKang Biological, and HaiZheng Pharmaceutical, suggesting these companies are currently favored by investors [3][4]

Core Insights - The animal health sector experienced a rise of 1.98% on October 10, with Bio-Pharmaceuticals leading the gains [1] - The Shanghai Composite Index closed at 3897.03, down 0.94%, while the Shenzhen Component Index closed at 13355.42, down 2.7% [1] Stock Performance - Bio-Pharmaceuticals (600201) closed at 10.16, up 4.42% with a trading volume of 808,300 shares and a transaction value of 815 million [1] - Other notable performers included: - Houbang Holdings (002141) at 3.85, up 3.77% [1] - Ruipu Biological (300119) at 21.87, up 3.16% [1] - Dayu Biological (920970) at 66.6, up 2.62% [1] - Huisheng Biological (300871) at 21.33, up 2.06% [1] Capital Flow - The animal health sector saw a net inflow of 111 million from institutional investors, while retail investors experienced a net outflow of 96.24 million [2] - The capital flow for key stocks included: - Bio-Pharmaceuticals (600201) with a net inflow of 73.87 million from institutional investors [3] - Huisheng Biological (300871) with a net inflow of 17.64 million from institutional investors [3] - Houbang Holdings (002141) with a net inflow of 16.38 million from institutional investors [3]

Group 1 - The pet economy concept stocks in the A-share market are experiencing a counter-trend rise, with notable increases in stock prices for several companies [1] - Yiyi Co., Ltd. reached a 10% limit up, while Babi Food increased by 6%, and other companies like Yuanfei Pet and Jieya Co. saw rises exceeding 5% [1] - The overall trend indicates a positive sentiment in the pet industry, as reflected by the MACD golden cross signal formation [1] Group 2 - Yiyi Co., Ltd. has a total market value of 6.346 billion and a year-to-date increase of 113.23% [2] - Babi Food has a market capitalization of 5.776 billion with a year-to-date increase of 45.81% [2] - Yuanfei Pet has a market value of 4.620 billion and a year-to-date increase of 54.05% [2] - Jieya Co. has a market capitalization of 3.847 billion and a year-to-date increase of 87.03% [2] - Petty Co. has a market value of 4.693 billion with a year-to-date increase of 8.49% [2] - Other companies like Biological Co. and Lusi Co. also showed significant increases in their stock prices and market values [2]

Group 1 - The A-share market's pet economy concept stocks are experiencing a counter-trend rise, indicating strong investor interest in this sector [1] - Yiyi Co., Ltd. has reached a 10% daily limit increase, showcasing significant market confidence [1] - Other notable performers include Babi Foods with a 6% increase, and Yuanfei Pet, Jeya Co., Ltd. with over 5% gains [1] Group 2 - Peti Co., Ltd., Bio Co., Ltd., Lusi Co., Ltd., and Shuangta Foods have all seen increases of over 4%, reflecting a broad positive sentiment in the pet industry [1] - Meino Biological, Haoyue Nursing, Ruipu Biological, and Chuangyuan Co., Ltd. have also reported gains exceeding 3%, further indicating the sector's resilience [1]

Group 1 - The core viewpoint of the news is that Bio Co., Ltd. has experienced a significant stock price increase, rising 5.24% to 10.24 CNY per share, with a total market capitalization of 11.384 billion CNY and a cumulative increase of 11.71% over the past four days [1] - Bio Co., Ltd. specializes in the research, production, and sales of veterinary biological products, with its main business revenue composition being 94.42% from biopharmaceuticals, 3.18% from other income, and 2.40% from supplementary sources [1] - The company is located in Hohhot, Inner Mongolia, and was established on March 13, 1993, with its listing date on January 15, 1999 [1] Group 2 - Southern Fund's Southern CSI 1000 ETF (512100) is among the top ten circulating shareholders of Bio Co., Ltd., having increased its holdings by 1.9417 million shares in the second quarter, now holding 10.3424 million shares, which is 0.92% of the circulating shares [2] - The ETF has generated a floating profit of approximately 5.2746 million CNY today and a total of 10.5492 million CNY during the four-day price increase [2] - The Southern CSI 1000 ETF was established on September 29, 2016, with a current scale of 64.953 billion CNY and a year-to-date return of 29.81%, ranking 2111 out of 4220 in its category [2]

Core Viewpoint - The stock price of Bio Co., Ltd. has shown significant growth this year, with a year-to-date increase of 45.39% and a recent surge of 14.01% over the last five trading days [2] Financial Performance - As of June 30, 2025, Bio Co., Ltd. reported a revenue of 620 million yuan, reflecting a year-on-year growth of 1.28%. However, the net profit attributable to shareholders decreased by 50.84% to 60.42 million yuan [2] - The company has cumulatively distributed dividends of 2.219 billion yuan since its A-share listing, with 18.9 million yuan distributed over the last three years [3] Stock Market Activity - The stock price reached 9.93 yuan per share with a market capitalization of 11.04 billion yuan as of October 10, 2023. The trading volume was 204 million yuan, with a turnover rate of 1.88% [1] - Bio Co., Ltd. has appeared on the "Dragon and Tiger List" twice this year, with the most recent net purchase of 123 million yuan on July 17, 2023 [2] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 3.84% to 54,900, with an average of 20,405 circulating shares per person, a decrease of 3.70% [2] - Major institutional shareholders include Guotai Zhenzhong Livestock Breeding ETF and Southern Zhenzhong 1000 ETF, with both increasing their holdings [3]